Ivor Lim | Founding Director & Group Chief Medical Officer
Cellresearch Corporation | Singapore

Ivor Lim, Founding Director & Group Chief Medical Officer, Cellresearch Corporation

Dr. Lim received his undergraduate medical training at Cambridge University and St. Thomas's Hospital (London), and qualified MBBChir (Cambridge). He is a Fellow of both the Royal College of Surgeons of Edinburgh, and the Royal College of Surgeons of Glasgow, as well as Master of Medicine (Surgery) from the National University of Singapore.

He is double exit certified in both Plastic Surgery and Hand Surgery from the Academy of Medicine, Singapore, as well as from the Intercollegiate Specialty Boards in the UK with FRCS (Plastic Surgery) qualifications.

Academically, Dr. Lim has been on Faculty in the Department of Surgery of the National University of Singapore since 1992. It was here that he started his research on scar biology and Umbilical Cord Lining Stem Cell biology with his close friend and colleague A/Prof Phan Toan Thang. 

He remains to this day an adjunct Associate Professor in Surgery, and continues to teach and conduct research there.

Dr. Lim is a Founder Director of Singapore Biotechnology Company CellResearch Corporation which focuses on Umbilical Cord Lining Stem Cell Research. The other 2 Founder Directors are A/Prof Phan Toan Thang and Mr. Gavin Tan. Cord Lining Stem Cell technology is now patent protected in 41 territories around the world.


Phar-East Day Two @ 09:50

Educated guesses, lofty aspirations, hard realities

Ideas are free and to be able to catch one by the wings and bring it back to ground is a wonderful feeling indeed. For doctors, the next step is to bring this good idea into the wards for the patient’s benefit. The transition of bench research to bedside application seems very straightforward at first glance, but it is not until the first steps are taken that one realises the numerous hurdles that have to be surmounted in order to achieve this. In the best interests of the patient, this translational sequence is prescriptive and tedious, and yet it pays no heed to other essentials crucial for the translational effort to be truly successful. This presentation also shares the journey of CellResearch Corporation which 13 years to see the light at the end of the tunnel.

back to speakers